{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:41:51Z","timestamp":1790948511508,"version":"4.1.0"},"reference-count":23,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To investigate the rare side effects of Osimertinib in a case of toxic epidermal necrosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation<\/jats:title>\n                    <jats:p>We report on a case of a 44-year old woman with lung adenocarcinoma harboring an EGFR-sensitizing mutation who was treated with Osimertinib as the second-line treatment. Ten days after Osimertinib initiation, a diffuse erythematous rash rapidly spread over the patient\u2019s trunk along with vesicles and purpuric macules; furthermore, she developed erythema and exfoliation on the face and trunk and severe mucositis. Toxic epidermal necrolysis (TEN) is life-threatening dermatologic adverse event, caused by a delayed-type drug hypersensitivity reaction. Although skin toxicity is common during treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), Osimertinib-associated TEN is very rare.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Treatment with systemic steroids and immunoglobulin as well as supportive treatment led to an improvement of her general wellbeing, followed by a remarkable recovery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although the clinical use of Osimertinib is becoming widespread, the side effects may not be fully understood. Clinicians should indeed pay more attention to the occurrence of side effects and be prepared to deal with them in timely manner.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/prilozi-2024-0025","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T17:22:05Z","timestamp":1734024125000},"page":"77-84","source":"Crossref","is-referenced-by-count":4,"title":["Osimertinib-Induced Toxic Epidermal Necrolysis  \u2013 A Case Report"],"prefix":"10.2478","volume":"45","author":[{"given":"Simonida","family":"Crvenkova","sequence":"first","affiliation":[{"name":"Faculty of Medicine , University Clinic of Radiotherapy and Oncology , Skopje , Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Popova","sequence":"additional","affiliation":[{"name":"Faculty of Medicine , University Clinic of Radiotherapy and Oncology , Skopje , Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Labina","family":"Crvenkova","sequence":"additional","affiliation":[{"name":"Faculty of Medicine , University Clinic of Cardiology , Skopje , Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonija","family":"Lazarevska","sequence":"additional","affiliation":[{"name":"Faculty of Medicine , University Clinic of Radiotherapy and Oncology , Skopje , Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"2026072617005084660_j_prilozi-2024-0025_ref_001","doi-asserted-by":"crossref","unstructured":"Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G.; et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129\u20132139.","DOI":"10.1056\/NEJMoa040938"},{"key":"2026072617005084660_j_prilozi-2024-0025_ref_002","doi-asserted-by":"crossref","unstructured":"Paez, J.G. EGFR Mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497\u20131500.","DOI":"10.1126\/science.1099314"},{"key":"2026072617005084660_j_prilozi-2024-0025_ref_003","unstructured":"Mok, T.S.; Wu, Y.L.; Ahn, M.J.; Garassino, M.C.; Kim, H.R.; Ramalingam, S.S.; Shepherd, F.A.; He, Y.; Akamatsu, H.; Theelen, W.S.; et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N. Engl. J. Med. 2016,"},{"key":"2026072617005084660_j_prilozi-2024-0025_ref_004","doi-asserted-by":"crossref","unstructured":"Lerch, M.; Mainetti, C.; Beretta-Piccoli, B.T.; Harr, T. Current perspectives on stevens-johnson syndrome and toxic epidermal necrolysis. Clin. Rev. Allergy Immunol. 2017, 54, 147\u2013176.","DOI":"10.1007\/s12016-017-8654-z"},{"key":"2026072617005084660_j_prilozi-2024-0025_ref_005","doi-asserted-by":"crossref","unstructured":"Lin, Y.T.; Chu, C. Osimertinib-induced Stevens-Johnson syndrome in a patient with EGFR T790M mutation-positive non-small cell lung cancer. Lung Cancer 2019, 129, 110\u2013111.","DOI":"10.1016\/j.lungcan.2018.12.030"},{"key":"2026072617005084660_j_prilozi-2024-0025_ref_006","doi-asserted-by":"crossref","unstructured":"Ko TM, et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol. 2011;128(6):1266\u201376.","DOI":"10.1016\/j.jaci.2011.08.013"},{"key":"2026072617005084660_j_prilozi-2024-0025_ref_007","doi-asserted-by":"crossref","unstructured":"De Araujo E, et al. Death ligand TRAIL, secreted by CD1a + and CD14 + cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis. Exp Dermatol. 2011; 20(2): 107\u201312.","DOI":"10.1111\/j.1600-0625.2010.01176.x"},{"key":"2026072617005084660_j_prilozi-2024-0025_ref_008","doi-asserted-by":"crossref","unstructured":"Mok TS, Wu YL, Ahn MJ et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017; 376: 629\u2013640.","DOI":"10.1056\/NEJMoa1612674"},{"key":"2026072617005084660_j_prilozi-2024-0025_ref_009","doi-asserted-by":"crossref","unstructured":"Ohe, Y.; Imamura, F.; Nogami, N.; Okamoto, I.; Kurata, T.; Kato, T.; Sugawara, S.; Ramalingam, S.S.; Uchida, H.; Hodge,R.; etal. Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Jpn. J. Clin. Oncol. 2019, 49, 29\u201336.","DOI":"10.1093\/jjco\/hyy179"},{"key":"2026072617005084660_j_prilozi-2024-0025_ref_010","doi-asserted-by":"crossref","unstructured":"Yang JC, Ahn MJ, Kim DW et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension compo nent. J Clin Oncol 2017; 35: 1288\u20131296.","DOI":"10.1200\/JCO.2016.70.3223"},{"key":"2026072617005084660_j_prilozi-2024-0025_ref_011","doi-asserted-by":"crossref","unstructured":"Goss G,Tsai CM, Shepherd FA et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): A multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2016; 17: 1643\u20131652.","DOI":"10.1016\/S1470-2045(16)30508-3"},{"key":"2026072617005084660_j_prilozi-2024-0025_ref_012","doi-asserted-by":"crossref","unstructured":"Soria JC, Ohe Y,Vansteenkiste J et al. Osimertinib in untreated EGFR-mutated advanced non small-cell lung cancer. N Engl J Med 2017; 378: 113\u2013125.","DOI":"10.1056\/NEJMoa1713137"},{"key":"2026072617005084660_j_prilozi-2024-0025_ref_013","doi-asserted-by":"crossref","unstructured":"Kozuki, T. Skin problems and EGFR-tyrosine kinase inhibitor. Jpn. J. Clin. Oncol. 2016, 46, 291\u2013298.","DOI":"10.1093\/jjco\/hyv207"},{"key":"2026072617005084660_j_prilozi-2024-0025_ref_014","doi-asserted-by":"crossref","unstructured":"Chung,W.H.; Hung, S.I.; Hong, H.S.; Hsih, M.S.; Yang, L.C.; Ho, H.C.; Wu, J.Y.; Chen, Y.T. Medical genetics: Amarker for Stevens-Johnson syndrome. Nature 2004, 428, 486.","DOI":"10.1038\/428486a"},{"key":"2026072617005084660_j_prilozi-2024-0025_ref_015","doi-asserted-by":"crossref","unstructured":"Khoo, A.; Foo, C. Toxic epidermal necrolysis in a burns centre: A 6-year review. Burns 1996, 22, 275\u2013278.","DOI":"10.1016\/0305-4179(95)00140-9"},{"key":"2026072617005084660_j_prilozi-2024-0025_ref_016","doi-asserted-by":"crossref","unstructured":"Roujeau, J.C.; Kelly, J.P.; Naldi, L.; Rzany, B.; Stern, R.S.; Anderson, T.; Auquier, A.; Bastuji-Garin, S.; Correia, O.; Locati, F.; et al. Medication use and the risk of stevens\u2013johnson syndrome or toxic epidermal necrolysis. N. Engl. J. Med. 1995, 333, 1600\u20131608.","DOI":"10.1056\/NEJM199512143332404"},{"key":"2026072617005084660_j_prilozi-2024-0025_ref_017","doi-asserted-by":"crossref","unstructured":"Lonjou, C.; Thomas, L.; Borot, N.; Ledger, N.; De Toma, C.; LeLouet, H.; Graf, E.; Schumacher, M.; Hovnanian, A.; Mockenhaupt,M.; etal. AmarkerforStevens-Johnsonsyndrome: Ethnicitymatters. Pharm. J. 2006, 6, 265\u2013268.","DOI":"10.1038\/sj.tpj.6500356"},{"key":"2026072617005084660_j_prilozi-2024-0025_ref_018","doi-asserted-by":"crossref","unstructured":"Wang, J.; Cheng, X.; Lu, Y.; Zhou, B. A case report of toxic epidermal necrolysis associated with AZD-9291. Drug Des. Dev. Ther. 2018, 12, 2163\u20132167.","DOI":"10.2147\/DDDT.S168248"},{"key":"2026072617005084660_j_prilozi-2024-0025_ref_019","doi-asserted-by":"crossref","unstructured":"Huang, J.J.; Ma, S.-X.; Hou, X.; Wang, Z.; Zeng, Y.D.; Qin, T.; Dinglin, X.X.; Chen, L.K. Toxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination therapy in a patient with metastatic non-small cell lung cancer. Chin. J. Cancer 2015, 34, 94\u201398","DOI":"10.5732\/cjc.014.10151"},{"key":"2026072617005084660_j_prilozi-2024-0025_ref_020","doi-asserted-by":"crossref","unstructured":"Doesch, J.; Debus, D.; Meyer, C.; Papadopoulos, T.; Schultz, E.S.; Ficker, J.H.; Brueckl, W. Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient. Lung Cancer 2016 95, 35\u201338.","DOI":"10.1016\/j.lungcan.2016.02.015"},{"key":"2026072617005084660_j_prilozi-2024-0025_ref_021","doi-asserted-by":"crossref","unstructured":"Otsuka,T; Tanaka,A.;Azukizawa,H.; Sasaki,S.; Ishijima,M.; Matsuki,T.; Osa,A.; Nakatani,T.; Kuroyama,M.; Hirata, H.; et al. Successful treatment with gefitinib after Stevens\u2013Johnson syndrome associated with afatinib therapy in apatient with adenocarcinoma of the lung. Int. Cancer Conf. J. 2016, 6, 38\u201341","DOI":"10.1007\/s13691-016-0269-3"},{"key":"2026072617005084660_j_prilozi-2024-0025_ref_022","doi-asserted-by":"crossref","unstructured":"Rittberg R, Ho C, Wang Y. Acute Onset of a Life-Threatening Skin Toxicity Due to Osimertinib: Severe Psoriasis Versus Toxic Epidermal Necrolysis Cureus. 2022 Apr 26; 14(4): e24513.","DOI":"10.7759\/cureus.24513"},{"key":"2026072617005084660_j_prilozi-2024-0025_ref_023","doi-asserted-by":"crossref","unstructured":"Yunhua Xu,, Yong Li, Jie Luo and Rong Tang Osimertinib-induced Keratitis and Secondary Toxic Epidermal Necrotic Drug Eruption- A Case Report and Literature Review Current Drug Safety, 2024, 19, 309\u2013312.","DOI":"10.2174\/1574886318666230529123200"}],"container-title":["PRILOZI"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/prilozi-2024-0025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T17:01:00Z","timestamp":1785085260000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/prilozi-2024-0025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,12,12]]},"published-print":{"date-parts":[[2024,11,1]]}},"alternative-id":["10.2478\/prilozi-2024-0025"],"URL":"https:\/\/doi.org\/10.2478\/prilozi-2024-0025","relation":{},"ISSN":["1857-8985"],"issn-type":[{"value":"1857-8985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}